Redefining the real problem in psychedelic trials: Why fighting the Lessebo matters more than blinding integrity

Bottom line: The real problem in psychedelic trials isn’t perfect blinding — it’s the way people feel when they’re told they’re getting a fake pill.

In a lab in Switzerland, a participant in a psychedelic trial is given a pill labeled “placebo” and told it’s just a sugar cube. They take it. Days later, they feel worse. Not because the pill had any effect — but because they were told it wouldn’t.

This is the Lessebo effect — a negative placebo reaction driven by the expectation that a placebo won’t work. And it’s not a minor issue. It’s a fundamental challenge that’s changing how we think about these trials.

The debate around blinding in these studies has been intense, with critics arguing that participants can often guess which group they’re in. But the real issue isn’t whether people can guess their treatment — it’s what happens after they do.

A new study in the International Journal of Drug Policy argues that the focus on perfect blinding is a distraction. The real problem lies in the emotional response to being told you’re in the control group. It’s not about whether you know what you’re getting — it’s about how you feel when you’re told you’re not getting anything at all.

The Hidden Cost of Placebo: Why Blinding Isn’t the Real Problem

Blinding in clinical trials is meant to prevent bias — participants don’t know if they’re getting the real treatment or a fake one. This is supposed to ensure that their expectations don’t influence the results. But in psychedelic research, this ideal is often unattainable. Participants can often guess whether they’re in the active or control group, especially when the effects of psychedelics are so dramatic and immediate.

Yet, the study says this isn’t the main issue. The focus on blinding is a distraction. The real problem is the emotional reaction that follows when people are told they’re in the control group — and that their experience might be less profound than others.

This emotional response, known as the Lessebo effect, is a form of negative placebo — a reaction not to the treatment itself, but to the expectation that it won’t work.

The authors point out that this effect is not unique to psychedelics. In many mental health trials, participants are often seen as unreliable reporters. But this view ignores the well-documented limitations of clinician-rated scales and the lack of biological markers for mental health improvement. Instead of questioning the validity of patient-reported outcomes, the study suggests we should question the assumptions that underlie how we design these trials.

The Lessebo Effect: A Double-Edged Sword

The Lessebo effect is a phenomenon where participants in a placebo group experience negative outcomes because they expect the placebo to be ineffective. This is different from the classic placebo effect, where people feel better because they believe they’re getting treatment. In the case of Lessebo, the expectation is that the placebo won’t work, and that expectation leads to negative emotions.

The study argues that this effect is not just a byproduct of imperfect blinding — it’s a consequence of how we frame the treatment. When participants are told they’re in a control group, they’re often given a narrative that implies their experience will be less meaningful or less transformative. This can create a sense of disappointment, which then influences their reported outcomes.

The authors suggest that this disappointment is often the result of insufficient clinical management. In other words, the problem isn’t just that people are told they’re getting a placebo — it’s that they’re not prepared for the possibility that their experience might still be meaningful.

This lack of preparation can lead to a sense of disillusionment, which then affects how they report their symptoms.

A New Approach: Mitigating Disappointment, Not Blinding

The study proposes a shift in focus from preserving blinding to mitigating disappointment. Instead of trying to make sure participants don’t know which group they’re in, the authors suggest that we should focus on managing the expectations that come with being in a control group.

This could involve structured psychoeducation, a stronger therapeutic alliance, and more realistic preparation for the experience.

Psychoeducation could include information about the nature of placebo effects and how they can influence outcomes. A strong therapeutic alliance could help participants feel more supported and less isolated in their experience. Realistic preparation might involve setting expectations that the control group experience can still be meaningful, even if it doesn’t involve the active treatment.

By addressing these emotional and psychological factors, the study argues that we can improve the ethical rigor and interpretability of psychedelic trials. This approach would not only make the trials more fair and transparent but also more clinically useful. It would allow researchers to better understand the true effects of psychedelics without being confounded by the emotional responses of participants.

Frequently Asked Questions

Q: Is blinding still important in psychedelic trials?
A: Yes, but the study argues that the focus should shift from perfect blinding to managing the emotional responses that come with being in a control group. Blinding is still important, but it’s not the only factor that affects the results of these trials.

Q: Can the Lessebo effect be prevented?
A: The study suggests that it can be mitigated through structured psychoeducation, a stronger therapeutic alliance, and realistic preparation. These strategies can help participants feel more supported and less disappointed in their experience.

Q: Are all participants in the control group affected by Lessebo?
A: No. The study acknowledges that some people in the control group may still have positive experiences. The Lessebo effect is not a universal problem, but it is a significant factor that should not be ignored.

Q: How does the Lessebo effect impact the results of psychedelic trials?
A: The Lessebo effect can lead to negative outcomes in the control group, which can confound the results of the trial. By addressing this effect, researchers can improve the accuracy and interpretability of their findings.

Q: What are the implications of this study for future psychedelic research?
A: The study suggests that future research should focus on managing the emotional and psychological factors that can influence outcomes. This approach would make trials more ethical, interpretable, and clinically useful.

Sources

• ¶Redefining the real problem in psychedelic trials: Why fighting the Lessebo matters more than blinding integrity
• ¶Redefining the real problem in psychedelic trials: Why fighting the Lessebo matters more than blinding integrity

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.